Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday ...

BioNTech has experienced a significant shift in its financial standing, reporting a net loss of €315.1m ($339.3m) in the ...

Welcome to BioNTech's First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead.

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the ...

BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines ...

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $146.00. Tazeen Ahmad’s ...

Reeling from “endemic-level demand” for its COVID-19 vaccine, BioNTech on Monday reported a steep decline in revenues and a ...

Chris Shibutani has given his Hold rating due to a combination of factors including BioNTech SE’s recent financial performance and future prospects. The company’s first-quarter earnings for 2024 were ...

BioNTech is a biotech company with a strong cash position and a commercial program generating cash-flow. Explore more details ...

Additionally, BioNTech’s diluted earnings per share dropped from €2.05 in Q1 2023 to a net loss per share of €1.31. Beyond the topline results, BioNTech’s quarterly R&D expenses totaled €507.5 million ...

By Helena Smolak BioNTech swung to a net loss in the first quarter on plummeted revenue after a sharp decline in its Covid-19 vaccine sales. The ...

German biotech BioNTech (Nasdaq: BNTX), which shot into the limelight with the development of the most successful COVID-19 vaccine, Comirnaty, has reported financial results for the three months ended ...